This study randomized 2:1 – 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year, the results were similar demonstrating the biolimus eluting stent noninferiority. At three years cardiac death, myocardial infarction and target vessel revascularization rates remained similar with 11% for biolimus eluting stent and 10.7% for the everolimus-eluting stent (p = 0.76).
Stent thrombosis was 1.2% for biolimus group and 0.8% for the everolimus group. In the subgroup analysis, the everolimus-eluting stent was superior in diabetic patients (p = 0.0378).
Conclusion
At 3-year follow up the biolimus eluting stent is equivalent to everolimus eluting stent.
Pieter Smits
2014-05-22
Title: The 3-year results from the COMPARE II trial
